We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Severe relapses of cutaneous T‐cell lymphoma after treatment of chronic graft‐versus‐host disease with ruxolitinib.
- Authors
Cohen, Elisabeth; Bozonnat, Alizée; Battistella, Maxime; Calvani, Julien; Vignon‐Pennamen, Marie‐Dominique; Rivet, Jacqueline; Moins‐Teisserenc, Hélène; Ta, Van‐Anh; Ram‐Wolff, Caroline; Bouaziz, Jean‐David; Mahevas, Thibault; Bagot, Martine; Mourah, Samia; Louveau, Baptiste; Sicre de Fontbrune, Flore; Peffault de Latour, Regis; de Masson, Adèle; Battesti, Gilles
- Abstract
This article discusses two cases of patients with cutaneous T-cell lymphoma (CTCL) who experienced severe relapses after receiving ruxolitinib, a JAK1/2 inhibitor, for the treatment of graft-versus-host disease (GVHD) following allogeneic stem cell transplantation (allo-HSCT). The patients initially showed positive responses to ruxolitinib for GVHD, but their CTCL worsened, leading to erythroderma and skin tumors. The authors suggest that ruxolitinib may have a deleterious effect on CTCL after allo-HSCT, possibly impairing the graft versus leukemia (GVL) response. Further investigation is needed to evaluate the use of JAK inhibitors in CTCL treatment after allo-HSCT.
- Subjects
GRAFT versus host disease; CUTANEOUS T-cell lymphoma; CANCER treatment; RUXOLITINIB; STEM cell transplantation; CHRONIC diseases
- Publication
Journal of the European Academy of Dermatology & Venereology, 2024, Vol 38, Issue 1, pe32
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.19408